

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

**INCREASE IN SHAREHOLDING OF H SHARES
BY THE CONTROLLING SHAREHOLDER**

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the company was notified by the controlling shareholder, Sichuan Kelun Pharmaceutical Co., Ltd. (“**Kelun Pharmaceutical**”) that Kelun Pharmaceutical acquired (through its wholly-owned subsidiary) 785,000 H shares of the Company at an average price of HK\$90.0 per H share by off-exchange block trade on January 22, 2024. Immediately after such acquisition, Kelun Pharmaceutical is interested in 150,123,385 shares of the Company, representing approximately 68.49% of the total issued shares of the Company.

By order of the Board

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

LIU Gexin

Chairman of the Board and Non-executive Director

Hong Kong, January 23, 2024

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.